Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).

NCT01097668 is registered in ClinicalTrials.gov with Apitope Technology (Bristol) Ltd. as lead sponsor.

NCT NCT01097668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01097668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).
Lead sponsor
Apitope Technology (Bristol) Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
July 31, 2013
Enrollment
43 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis